FR

A brief history

A look back at the origins of the Prism Center in a few dates

Prism is the first National Center for Precision Medicine in oncology. A unique partnership, bringing together four leading institutions: Gustave Roussy, CentraleSupélec, Inserm and University Paris-Saclay.

The recent origins of precision medicine date back to the 2000s and the first pilot trials aimed at evaluating molecular tumor profiling. Gustave Roussy for his part launched a first feasibility study of routine molecular profiling of tumors in 2008. A look back at the origins of the Prism Center in a few dates.

2008

=

Gustave Roussy launches a feasibility study, in 108 patients, of the routine use of DNA chips (CGH array).

2011

=

Gustave Roussy publishes a reference publication in precision medicine in the Journal of Clinical Oncology, which conceptualizes high-throughput tumor sequencing applied as a diagnostic tool

=

Safir 01 & Moscato 01 trials are launched.

2013

=

Inauguration of the « B2M » (for Bâtiment de Médecine Moléculaire), a research building entirely dedicated to molecular medicine.

2014

=

Results of the Safir 01 breast cancer study, showing the feasibility of clinical high-throughput sequencing, are published in Lancet Oncology.

=

Launch of Safir 02 to assess whether genomic analysis improves the management of patients with metastatic breast cancer.

2016

=

Launch of MAPPYACTS aimed at studying the genetic characteristics of childhood tumors or leukemia.

=

Launch of the MATCH-R trial to understand and identify the cellular mechanisms involved in resistance to targeted therapies

2019

=

Four Clinical Trials led by Gustave Roussy physicians, published in the New England Journal of Medicine, demonstrate that patients do benefit from therapies guided by genomic analysis.

2020

=

Launch of Prism. The center is labeled « National Center for Precision Medicine in oncology. » Prism is a consortium of Gustave Roussy, CentraleSupélec, Paris-Saclay University and Inserm.

2023

=

The Prism program was awarded the « Institut Hospitalo-Universitaire » (IHU) label by the French Government as part of the IHU3 call for projects of the France 2030 plan.